Bayer, Sysmex link to concoct companion Dx for targeted tumor treatments

Bayer, the German drugmaker, will join forces with Japanese diagnostics giant Sysmex to develop companion diagnostic tests for targeted cancer tumor treatments. Specifically, Sysmex's newly acquired Inostics division will develop blood-based companion diagnostic tests to be paired with targeted anticancer drugs advanced by Bayer HealthCare. They'll rely heavily on Sysmex Inostics' BEAMing technology that enables creation of extremely sensitive diagnostic tests that can screen for circulating tumor DNA cast off into the bloodstream. Neither side is disclosing financial details. Story